AAREYDRUGS

Aarey Drugs & Pharmaceuticals Limited

Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

aareydrugs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹112.91
Market cap
349 Cr
Stock P/E
65.8
P/B
2.13
ROE (FY26)
2.6%
ROCE (FY26)
5.2%
Operating margin (FY26)
0.9%
Debt / equity (FY26)
0.33

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Aarey Drugs & Pharmaceuticals manufactures and trades drugs and pharmaceuticals from a factory at Tarapur in Maharashtra.

Company snapshot

102ndBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Concerns
  • ✗Net margin is very thin at 0.8% — little room for error if costs rise.
1 more signal from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales58 Cr76 Cr210 Cr127 Cr105 Cr134 Cr108 Cr102 Cr84 Cr96 Cr189 Cr45 Cr
Operating expenses (approx.)56 Cr74 Cr212 Cr126 Cr101 Cr132 Cr113 Cr101 Cr82 Cr98 Cr185 Cr43 Cr
EBITDA2 Cr3 Cr-1 Cr1 Cr4 Cr2 Cr-5 Cr2 Cr3 Cr-2 Cr4 Cr1 Cr
OPM %3.2%3.5%-0.7%0.9%3.5%1.6%-4.5%1.7%3.1%-1.6%2.3%3.0%
Other income0.84 Cr0.29 Cr5 Cr2 Cr0.02 Cr0.68 Cr8 Cr2 Cr0.79 Cr4 Cr-0.43 Cr2 Cr
Interest1 Cr1 Cr1 Cr0.96 Cr2 Cr0.90 Cr2 Cr1 Cr1 Cr0.92 Cr2 Cr2 Cr
Depreciation0.41 Cr0.47 Cr0.40 Cr0.47 Cr0.49 Cr0.58 Cr-1 Cr0.49 Cr0.69 Cr0.83 Cr0.85 Cr0.85 Cr
Profit before tax1 Cr1 Cr2 Cr1 Cr2 Cr1 Cr2 Cr2 Cr1 Cr0.92 Cr1 Cr0.52 Cr
Tax %22.1%30.2%-0.3%6.9%8.6%48.7%71.1%20.6%30.9%-38.3%-21.7%-98.5%
Net profit0.78 Cr1 Cr2 Cr1 Cr2 Cr0.72 Cr0.47 Cr1 Cr1 Cr1 Cr2 Cr1 Cr
EPS (₹)₹0.31₹0.40₹0.77₹0.44₹0.57₹0.26₹0.04₹0.48₹0.36₹0.20₹0.55₹0.36

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales——300 Cr348 Cr493 Cr62 Cr396 Cr474 Cr472 CrSign in free for the trailing twelve months
Operating expenses (approx.)——297 Cr344 Cr481 Cr61 Cr391 Cr472 Cr465 CrSign in free for the trailing twelve months
EBITDA——3 Cr5 Cr11 Cr2 Cr4 Cr2 Cr7 CrSign in free for the trailing twelve months
OPM %——1.1%1.3%2.3%2.4%1.1%0.5%1.5%Sign in free for the trailing twelve months
Other income——7 Cr7 Cr3 Cr0.48 Cr7 Cr10 Cr6 CrSign in free for the trailing twelve months
Interest——2 Cr2 Cr2 Cr0.55 Cr4 Cr4 Cr5 CrSign in free for the trailing twelve months
Depreciation——0.89 Cr0.92 Cr2 Cr0.71 Cr2 Cr2 Cr3 CrSign in free for the trailing twelve months
Profit before tax——7 Cr8 Cr10 Cr0.75 Cr5 Cr6 Cr5 CrSign in free for the trailing twelve months
Tax %——20.0%21.5%24.9%33.7%12.3%34.1%26.7%Sign in free for the trailing twelve months
Net profit——6 Cr7 Cr8 Cr0.49 Cr5 Cr4 Cr4 CrSign in free for the trailing twelve months
EPS (₹)——₹2.48₹2.79₹2.72₹0.19₹1.84₹3.27₹1.39Sign in free for the trailing twelve months
Dividend payout %————0.0%0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital18 Cr23 Cr23 Cr23 Cr25 Cr25 Cr28 Cr28 Cr28 Cr
Reserves31 Cr57 Cr69 Cr75 Cr88 Cr92 Cr105 Cr110 Cr122 Cr
Borrowings10 Cr3 Cr18 Cr18 Cr14 Cr38 Cr31 Cr35 Cr50 Cr
Other liabilities83 Cr86 Cr84 Cr116 Cr117 Cr136 Cr141 Cr65 Cr97 Cr
Total liabilities142 Cr170 Cr194 Cr233 Cr245 Cr291 Cr305 Cr238 Cr297 Cr
Fixed assets (net)12 Cr12 Cr12 Cr14 Cr14 Cr14 Cr15 Cr16 Cr26 Cr
CWIP—0.34 Cr0 Cr—0 Cr0 Cr0 Cr0 Cr0 Cr
Investments0.44 Cr0.44 Cr0.44 Cr0.40 Cr0.40 Cr0.40 Cr1 Cr2 Cr2 Cr
Loans & advances——0.02 Cr—0.02 Cr9 Cr16 Cr30 Cr21 Cr
Inventories5 Cr15 Cr17 Cr18 Cr14 Cr29 Cr35 Cr45 Cr42 Cr
Trade receivables82 Cr95 Cr96 Cr162 Cr136 Cr190 Cr0 Cr130 Cr130 Cr
Cash & bank0.60 Cr0.52 Cr0.49 Cr0.65 Cr0.19 Cr0.71 Cr2 Cr1 Cr1 Cr
Other assets42 Cr47 Cr68 Cr37 Cr80 Cr49 Cr237 Cr13 Cr76 Cr
Total assets142 Cr170 Cr194 Cr233 Cr245 Cr291 Cr305 Cr238 Cr297 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity0.63 Cr-20 Cr3 Cr8 Cr19 Cr-39 Cr8 Cr10 Cr10 Cr
Cash from investing-5 Cr-0.60 Cr-0.92 Cr—24 Cr11 Cr-7 Cr-6 Cr-12 Cr
Cash from financing4 Cr23 Cr-2 Cr—4 Cr-23 Cr4 Cr-4 Cr2 Cr
Net cash flow-0.58 Cr2 Cr0.13 Cr8 Cr47 Cr-50 Cr5 Cr-0.12 Cr-0.07 Cr
Free cash flow (OCF − Capex)-4 Cr-21 Cr2 Cr—19 Cr-40 Cr8 Cr10 Cr-2 Cr

Ratios

MetricMar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %——8.2%9.2%9.4%0.8%5.9%5.8%5.2%
ROE %——6.3%6.6%6.6%0.4%3.5%2.9%2.6%
Debtor days——11716910111060100100
Inventory days——212010175333534
Days payable——9811807721214266
Cash conversion cycle——4171111509-899368
OCF / EBITDA %——n.m.n.m.n.m.n.m.n.m.n.m.n.m.
OCF / EBITDA % (3 years)————n.m.n.m.n.m.n.m.n.m.
Debt / equity0.210.040.190.180.120.320.240.250.33
Current ratio1.421.781.81—10.201.610.582.201.81
Net debt / EBITDA——5.43—1.2424.216.6914.836.77